A Study of PRN1008 in Patients With Pemphigus

  • End date
    Mar 26, 2022
  • participants needed
  • sponsor
    Principia Biopharma Inc.
Updated on 27 December 2020
Regan Burns
Primary Contact
Central Recruiting (Principia Biopharma) (8.7 mi away) Contact
+158 other location
renal function
pemphigus foliaceus
autoantibody titer


This is a Phase 3 randomized, parallel-group, double-blind, placebo-controlled trial (Blinded Treatment Period) followed by an Open-Label Extension Period intended to evaluate the efficacy and safety of oral PRN1008 in moderate to severe pemphigus. After completing the Open-Label Extension Period, eligible patients may continue in a Long Term Extension Period of 48 weeks.


Approximately 120 male or female patients with newly diagnosed or relapsing moderate to severe pemphigus (pemphigus vulgaris [PV] or pemphigus foliaceus [PF]) will be enrolled in the trial worldwide.

The trial will last 68 weeks (approximately 17 months) for each participant. For patients eligible to enroll in the Long Term Extension, the trial may last up to 116 weeks.

Patients will be randomized at Day 1, using a 1:1 ratio to receive PRN1008 or placebo twice per day, by relapsing/newly diagnosed disease history (newly diagnosed defined as within 6 months of Screening).

Treatment Placebo Oral Tablet, PRN1008 Oral Tablet
Clinical Study IdentifierNCT03762265
SponsorPrincipia Biopharma Inc.
Last Modified on27 December 2020

Adding a note
adding personal notes guide

Select a piece of text and start making personal notes.

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer


user name

Annotated by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No made yet